問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Dalin Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation

Recruiting

List

31Cases

2019-10-31 - 2023-10-05

Phase II

Completed
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

  • Condition/Disease

    Systemic Lupus Erythematosus（SLE)

  • Test Drug

    PF-06700841

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2028-03-31

Phase I/II

Active
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

  • Condition/Disease

    Non Small Cell Lung Carcinoma

  • Test Drug

    N/A

Participate Sites
8Sites

Recruiting8Sites

2019-03-06 - 2022-02-28

Phase II

Active
Phase 2 open trial to evaluate the safety and efficacy of Telisotuzumab Vedotin (ABBV-399) in subjects with previously treated c-Met+ non-small cell lung cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    Telisotuzumab Vedotin (ABBV-399)

Participate Sites
11Sites

Recruiting11Sites

2022-08-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-12-14 - 2026-12-31

Phase III

Active
A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

  • Condition/Disease

    Gout

  • Test Drug

    錠劑

Participate Sites
13Sites

Recruiting13Sites

2021-03-01 - 2028-12-31

Phase III

Completed
A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  • Condition/Disease

    Idiopathic Pulmonary Fibrosis

  • Test Drug

    PRM-151 (Zinpentraxin Alfa)

Participate Sites
7Sites

Recruiting7Sites

2020-01-06 - 2026-09-05

Phase III

Active
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Selpercatinib (LY3527723)

Participate Sites
14Sites

Recruiting14Sites

2025-04-01 - 2032-12-31

Phase III

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02

  • Condition/Disease

    Non–small cell lung cancer (NSCLC)

  • Test Drug

    Durvalumab Olomorasib Pembrolizumab

Participate Sites
18Sites

Recruiting18Sites

2024-01-01 - 2030-12-31

Phase III

Active
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung 、Neoplasm Metastasis

  • Test Drug

    N/A N/A N/A N/A N/A

Participate Sites
17Sites

Recruiting17Sites

2023-06-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Recruiting19Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB